Clinical Stage Program Updates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress Affimed N.V.April 15, 2021 GMT AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion coh...